23andMe Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Explore the Complete Value Chain Behind the Preview
This 23andMe Value Chain Analysis gives you a clear, company-specific breakdown of how 23andMe creates value through its support and primary activities. The page already shows a real preview of the actual analysis, so you can review the content before buying. Purchase the full version to get the complete ready-to-use report instantly.
Support Activities
Firm Infrastructure
23andMe's firm infrastructure sits under a heavy HIPAA and FDA burden, and that matters because it supports a base of more than 15 million genotyped customers while protecting sensitive health data. In FY2025, the company also had to keep compliance tight as it shifted from low-margin consumer testing toward higher-margin therapeutic research deals.
This pivot needs strong legal, finance, and governance controls, because one misstep can cut off access to healthcare markets and partner trust. The challenge got sharper in 2025, when 23andMe entered Chapter 11 on March 23, 2025, showing how quickly cash, regulation, and operating discipline can collide.
So, firm infrastructure is not back-office support here; it is the system that keeps the business licensed, fundable, and able to handle biological and genomic data at scale.
Human Resource Management
23andMe's human resource management hinges on keeping bioinformaticians, data scientists, and genetics researchers aligned with a database of more than 15 million consented customers. That talent mix matters in 2025 because the company must retain elite technical staff for drug discovery while keeping sales teams tuned to a subscription model. Matching workforce skills to biopharma goals cuts the friction of shifting from consumer genomics to drug development.
Technology Development
23andMe's technology development centers on a proprietary genomic database built from more than 15 million genotyped customers, which feeds machine learning models for novel drug targets and health risk prediction. The company keeps upgrading its custom genotyping chips and cloud data stack to handle multi-petabyte datasets faster and at lower cost. That IP-rich data moat raises switching costs and acts as a barrier to entry for rivals.
Procurement
In FY2025, 23andMe's procurement centered on bulk FDA-cleared saliva kits, long-term genotyping lab contracts, and cloud deals that support global data storage. That matters because FY2025 revenue was about $193 million, so small savings on kit and lab sourcing can move unit economics fast while keeping large-scale genomic processing reliable.
23andMe's FY2025 Backbone: Compliance, Talent, and Scale Under Pressure
23andMe's support activities in FY2025 were built to protect regulated genetic data, keep specialized staff aligned with drug discovery, and run a costly lab-and-cloud supply chain while revenue fell to about $193 million. Firm infrastructure and compliance stayed central after Chapter 11 on March 23, 2025, because they kept the Company licensed, trusted, and able to handle more than 15 million genotyped customers.
| Support activity | FY2025 signal |
|---|---|
| Infrastructure | Chapter 11, Mar 23, 2025 |
| HR | Bioinformatics and research talent |
| Procurement | Saliva kits, lab and cloud contracts |
| Scale | 15M+ genotyped customers |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
23andMe's inbound logistics starts with shipping saliva kits to customers and moving stabilized samples back to certified labs for genotyping. The company relies on integrated courier routes and barcode tracking so each sample stays linked to one customer and spends less time in transit, which protects data integrity. In 2025, this chain remained core to a model built on direct-to-consumer sample collection and lab processing.
Operations
23andMe's Operations center on high-throughput genotyping of saliva DNA, with each sample analyzed for more than 650,000 genetic markers. In FY2025, its platform still served over 15 million customers, showing how scale matters in turning lab output into product.
After lab work, bioinformatics pipelines convert sequence data into digital health and ancestry reports inside the user app. That automated flow cuts manual work and turns one raw sample into repeatable, low-marginal-cost insights.
Outbound Logistics
Outbound logistics at 23andMe are mostly digital: once lab processing ends, results move through encrypted web and mobile apps, so each extra report has near-zero delivery cost. The company has served over 15 million customers, which shows why scalable digital fulfillment matters more than physical shipping.
For pharma partners, outbound logistics mean curated, anonymized data transfers that support drug discovery, not product shipping. This model turns a single genotyping workflow into multiple revenue uses, while keeping fulfillment fast and low cost.
Marketing and Sales
23andMe uses an omnichannel model: digital direct-to-consumer ads, retail shelves, and the 23andMe+ subscription. With more than 15 million customers in its database, marketing pushes the long life of genetic data, so users stay for new health and trait updates.
This supports a recurring revenue mix, which can lift lifetime value versus one-time saliva kit sales.
Service
23andMe's service keeps the first sale alive by refreshing reports as new genetics research lands, so the value grows over time. Its digital counseling tools and family-tree features help users stay engaged, while privacy controls let customers choose research participation. With a database of 15 million+ genotyped customers, trust is central to keeping the biobank active and expanding.
23andMe's FY2025 Engine: 15M+ Customers Powering Low-Touch Consumer Genetics
23andMe's primary activities in FY2025 were direct-to-consumer kit distribution, saliva sample genotyping, and digital delivery of ancestry and health reports. Its scale still rested on a database of more than 15 million customers, so each tested sample could feed both consumer insights and research use. The model stays low-touch after lab work, with results moving through the app.
| FY2025 metric | Value |
|---|---|
| Customers in database | 15M+ |
Preview Before You Purchase
23andMe Reference Sources
This is the actual 23andMe Value Chain Analysis document you'll receive upon purchase – no surprises, just the full professional version. The preview below is taken directly from the final report, so what you see here is what you get. Once purchased, the complete in-depth analysis becomes available immediately.
Frequently Asked Questions
Privacy is fundamental, as over 80 percent of customers currently opt into research. The company utilizes a double-blind process where labs only see barcode IDs rather than names. This framework protects 15 million profiles, ensuring compliance with international regulations and securing the long-term viability of their 5-year pharmaceutical data partnerships.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.